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ABSTRACT 
Background: Folic acid fortification of grains is mandated in many countries to prevent neural 
tube defects. Concerns regarding excessive intakes of folic acid have been raised. A synthetic 
analog of the circulating form of folate, l-5-methyltetrahydrofolate (l-5-MTHF), may be a 
potential alternative. Objective: The objective of this study was to determine the effects of folic 
acid or l-5-MTHF supplementation on blood folate concentrations, methyl nutrient metabolites, 
and DNA methylation in women living in Malaysia, where there is no mandatory fortification 
policy. Methods: In a 12-wk, randomized, placebo-controlled intervention trial, healthy 
Malaysian women (n = 142, aged 20–45 y) were randomly assigned to receive 1 of the 
following supplements daily: 1 mg (2.27 μmol) folic acid, 1.13 mg (2.27 μmol) l-5-MTHF, or 
a placebo. The primary outcomes were plasma and RBC folate and vitamin B-12 
concentrations. Secondary outcomes included plasma total homocysteine, total cysteine, 
methionine, betaine, and choline concentrations and monocyte long interspersed nuclear 
element-1 (LINE-1) methylation. Results: The folic acid and l-5-MTHF groups had higher (P 
< 0.001) RBC folate (mean ± SD: 1498 ± 580 and 1951 ± 496 nmol/L, respectively) and plasma 
folate [median (25th, 75th percentiles): 40.1 nmol/L (24.9, 52.7 nmol/L) and 52.0 nmol/L (42.7, 
73.1 nmol/L), respectively] concentrations compared with RBC folate (958 ± 345 nmol/L) and 
plasma folate [12.6 nmol/L (8.80, 17.0 nmol/L)] concentrations in the placebo group at 12 wk. 
The l-5-MTHF group had higher RBC folate (1951 ± 496 nmol/L; P = 0.003) and plasma folate 
[52.0 nmol/L (42.7, 73.1 nmol/L); P = 0.023] at 12 wk than did the folic acid group [RBC 
folate, 1498 ± 580 nmol/L; plasma folate, 40.1 nmol/L (24.9, 52.7 nmol/L)]. The folic acid and 
l-5-MTHF groups had 17% and 15%, respectively, lower (P < 0.001) plasma total 
homocysteine concentrations than did the placebo group at 12 wk; there were no differences 
between the folic acid and l-5-MTHF groups. No differences in plasma vitamin B-12, total 
cysteine, methionine, betaine, and choline and monocyte LINE-1 methylation were observed. 
Conclusion: These findings suggest differential effects of l-5-MTHF compared with folic acid 
supplementation on blood folate concentrations but no differences on plasma total 
homocysteine lowering in Malaysian women. This trial was registered at clinicaltrials.gov as 
NCT01584050. 
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